Fate Therapeutics, Inc.
FATE
$1.90
-$0.01-0.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.11% | -21.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.11% | -21.37% | |||
| Cost of Revenue | 160.17% | -63.25% | |||
| Gross Profit | -188.01% | 66.28% | |||
| SG&A Expenses | -62.36% | 139.66% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.97% | -4.07% | |||
| Operating Income | 1.85% | 3.21% | |||
| Income Before Tax | 3.59% | -0.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.59% | -0.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.59% | -0.38% | |||
| EBIT | 1.85% | 3.21% | |||
| EBITDA | 1.56% | 3.02% | |||
| EPS Basic | 4.24% | -0.18% | |||
| Normalized Basic EPS | 0.85% | 3.25% | |||
| EPS Diluted | 4.24% | -0.18% | |||
| Normalized Diluted EPS | 0.85% | 3.25% | |||
| Average Basic Shares Outstanding | 0.66% | 0.21% | |||
| Average Diluted Shares Outstanding | 0.66% | 0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||